A lab study reports that the choice of storage buffer can alter mRNA lipid nanoparticle structure, stability, and cell-delivery performance after refrigerated storage or freezing. The findings suggest that formulation variables—often treated as logistics—can materially influence how well mRNA reaches target cells. For developers running cold-chain manufacturing and long-term storage qualification, the work points to a deeper quality-by-design requirement: stability testing and functional delivery assays need to be integrated for each buffer condition, not inferred from chemistry alone. The report is preclinical, but it directly informs process development for mRNA therapeutics where small formulation differences can drive large differences in potency and consistency.